Surface Oncology(SURF)

令狐不冲9992020-10-13 21:06

$Surface Oncology(SURF)$ 高位漫长而强势的整理，往往必有所图查看全文

追风筝的鱼roy2020-10-13 07:41

$Surface Oncology(SURF)$ GSK要买。。。。查看全文

LAES1682020-10-13 00:36

$Surface Oncology(SURF)$boom查看全文

看看eh3溪水长流2020-10-06 16:42

$Surface Oncology(SURF)$看来近期要表现下了查看全文

看看eh3溪水长流2020-09-23 22:01

$Surface Oncology(SURF)$ cd47项目注定比pd1还要出彩。查看全文

令狐不冲9992020-08-28 21:23

8.28盘前异动： $Nutanix(NTNX)$ $Surface Oncology(SURF)$ $Peloton Interactive(PTON)$查看全文

牛唐2020-08-09 17:20

$延龄草治疗(TRIL)$ $ALX Oncology(ALXO)$ $Surface Oncology(SURF)$ cd47概念股查看全文

追风筝的鱼roy2020-06-25 09:26

$Surface Oncology(SURF)$ CD112R用不了多久就会合作出去了，，看看是罗氏还是默克？查看全文

牛唐2020-06-19 13:56

cd47的$延龄草治疗(TRIL)$ 还在升温，cd73的$Surface Oncology(SURF)$ &$Corvus制药(CRVS)$ 继续接力查看全文

chuminhua2020-05-21 12:47

5/20，Surface Oncology$Surface Oncology(SURF)$ 宣布，已与默沙东（MSD）$默沙东(MRK)$ 达成了一项临床试验合作，旨在评估其开发的CD39抑制剂SRF617，与默沙东的重磅PD-1抑制剂Keytruda联合，治疗实体瘤患者的安全性和有效性。这种联合疗法将作为SRF617首次1/1b期临床研究的一个组成部分，其重点...查看全文

传葛兰素史克(GSK.US)有意收购Surface Oncology(SURF.US)

智通财经APP获悉，据媒体消息，专攻免疫疗法的Surface Oncology(SURF.US)公司收到了葛兰素史克(GSK.US)的收购意向。 报道称，除葛兰素史克之外，Surface Oncology还在寻找其它任何可能的收购者。 此前，百时美施贵宝(BMY.US)在同意收... 网页链接

其他

$Surface Oncology(SURF)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0001193125-23-236303  Act: 34  Size: 12 KB 网页链接

生效批准

$Surface Oncology(SURF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002629  Act: 33  Size: 1 KB 网页链接

生效批准

$Surface Oncology(SURF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002628  Act: 33  Size: 1 KB 网页链接

招股信息更正说明

$Surface Oncology(SURF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-23-231522  Act: 33  Size: 21 KB 网页链接

其他

$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231530  Act: 33  Size: 23 KB 网页链接

其他

$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231534  Act: 33  Size: 23 KB 网页链接

其他

$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231535  Act: 33  Size: 23 KB 网页链接

其他

$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231539  Act: 33  Size: 23 KB 网页链接

其他

$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231542  Act: 33  Size: 23 KB 网页链接

其他

$Surface Oncology(SURF)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-23-231544  Act: 33  Size: 23 KB 网页链接